 |
인쇄하기
취소
|
Dong-A to conduct phase I trial for new treatment of premature ejaculation
Dong-A Pharmaceutical Co. said on May 4 it will conduct its Phase I trial for a new medicine (codename: DA-8031) for the treatment of premature ejaculation (PE).
The company said the study will be conducted in Seoul National University Hospital.
DA-8031 is shown to be effective in animal studies with less side effects, such as dizziness and nausea.
Janssen’s oral Priligy (dapoxetin) is...
The company said the study will be conducted in Seoul National University Hospital.
DA-8031 is shown to be effective in animal studies with less side effects, such as dizziness and nausea.
Janssen’s oral Priligy (dapoxetin) is...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.